THER has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
THER has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Theralink Technologies's Average Total Inventories for the three months ended in Dec. 2023 was $0.00 Mil. Theralink Technologies's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.05 Mil. Hence, Theralink Technologies's Days Inventory for the three months ended in Dec. 2023 was 0.00.
The historical rank and industry rank for Theralink Technologies's Days Inventory or its related term are showing as below:
Theralink Technologies's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Theralink Technologies's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.00.
The historical data trend for Theralink Technologies's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralink Technologies Annual Data | |||||||||||||||||||||
Trend | Feb14 | Feb15 | Dec16 | Dec17 | Dec18 | Dec19 | Sep20 | Sep21 | Sep22 | Sep23 | |||||||||||
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
- | 498.37 | 219.62 | 115.18 | - |
Theralink Technologies Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Theralink Technologies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Theralink Technologies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Theralink Technologies's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Theralink Technologies's Days Inventory for the fiscal year that ended in Sep. 2023 is calculated as
Days Inventory (A: Sep. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Sep. 2022 ) | + | Total Inventories (A: Sep. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Sep. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0.126 | * | 365 |
= | 0 | / | 0.126 | * | 365 | ||||
= | 0.00 |
Theralink Technologies's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:
Days Inventory (Q: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0.053 | * | 365 / 4 |
= | 0 | / | 0.053 | * | 365 / 4 | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralink Technologies (OTCPK:THER) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Theralink Technologies's Inventory Turnover for the three months ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0.053 | / | 0 | |
= |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Theralink Technologies's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0.084 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Theralink Technologies's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Danica Holley | director | 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
Matthew Wilson Schwartz | director | 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401 |
Chilcott, Iii Thomas E. | officer: Chief Financial Officer | 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122 |
Jeffrey Busch | director | 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814 |
Yvonne Fors | director | 1201 MONSTER RD SW STE 350, RENTON WA 98057 |
Michael I Ruxin | director, officer: Chief Executive Officer | HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184 |
Avant Diagnostics, Inc | 10 percent owner | 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007 |
Brian Gill Barnett | officer: Chief Executive Officer | 230 N SPRINGER, LOS ALTOS CA 94024 |
Robert Neal Holcomb | director | PO BOX 535, ROLLING FORK MS 39159 |
Volnie Carlos Fernando Alaman | 10 percent owner, officer: Chief Operating Officer-Vitel | MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
Odabachian Manuel Cosme | director, 10 percent owner, officer: Global Operations GM-Vitel | MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000 |
Daniel S. Hoverman | director | C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809 |
Rice Charles L Jr | director | C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
Andrew Albert Kucharchuk | director, officer: CFO & President | 549 MILGATE PLACE, BATON ROUGE LA 70810 |
Jonathan Frederick Head | director, officer: Chief Executive Officer | 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817 |
From GuruFocus
By PRNewswire PRNewswire • 12-06-2022
By Marketwired • 06-27-2023
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 09-01-2020
By GuruFocus Research • 02-15-2024
By PRNewswire PRNewswire • 09-24-2020
By PRNewswire PRNewswire • 02-23-2023
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 11-29-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.